Biogen Stays Steady As Alzheimer’s Programs Falter

 
• By Mary Jo Laffler
  
Risk Dial
Biogen's high-risk pipeline has investors concerned
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business